
Evidence analysis
Smugglers Collected Up to $509M on Europe Routes in 2025
Smugglers’ Revenue from Mediterranean and Atlantic Migration Routes to Europe in 2025: Evidence Dossier What is established New research conducted by the United Nations Office on Drugs and Crime (UNODC) estimates that in 2025, criminal smuggling networks collected…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Filgrastim Hexal, filgrastim, Date of authorisation: 06/02/2009, Revision: 27, Status: Authorised
What is established Filgrastim Hexal is an authorised biosimilar medicine approved by the European Medicines Agency (EMA). It contains the active substance filgrastim, a recombinant form of human granulocyte colony stimulating factor (G-CSF), which stimulates the production of…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 8, Status: Authorised
What is established Cejemly (active substance: sugemalimab) is a medication authorized by the European Medicines Agency (EMA) for the treatment of non-small cell lung cancer (NSCLC) in adults. It is indicated specifically for: Patients with metastatic NSCLC lacking…
Read →
Evidence analysis
Protect yourself and others during the cold season
Evidence Dossier: Protecting Against Respiratory Infections During the Cold Season in Europe What is established Respiratory infections such as influenza, respiratory syncytial virus (RSV), COVID-19, and pneumococcal disease pose significant health challenges in Europe, especially during colder months.…
Read →
Evidence analysis
Respiratory infections season
What is established As Europe enters the colder months, respiratory infections commonly see an increase in incidence. Key respiratory pathogens involved are influenza viruses, respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19), and bacteria causing pneumococcal disease. These infections can…
Read →
Evidence analysis
Seeing the invisible: Reorienting cardiovascular risk prediction across the disease trajectory
What is established Cardiovascular risk prediction has been a central component of preventive medicine for decades. Traditional risk equations such as the Framingham model, Pooled Cohort Equations, SCORE2, QRISK4, PREDICT, and China-PAR estimate an individual's absolute risk of…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Vyvgart, efgartigimod alfa, Date of authorisation: 10/08/2022, Revision: 11, Status: Authorised
What is established Vyvgart (efgartigimod alfa) is an authorised medicine in the European Union for adults with two rare neuromuscular autoimmune disorders: generalised myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). Both diseases involve an abnormal immune…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): GONAL-f, follitropin alfa, Date of authorisation: 20/10/1995, Revision: 28, Status: Authorised
What is established GONAL-f, containing the active substance follitropin alfa, is a medicine authorised in the European Union since 1995. It is manufactured by Merck Serono Europe Ltd and is used primarily in fertility treatments. Follitropin alfa is…
Read →
Evidence analysis
Plasma proteomic signatures of subclinical atherosclerosis progression for cardiovascular risk stratification: A cohort study
What is established Atherosclerosis, a condition characterized by the buildup of plaques in arterial walls, is a major underlying cause of cardiovascular diseases (CVD), including heart attacks and strokes. Traditional risk assessments for cardiovascular disease typically incorporate factors…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Darunavir Viatris (previously Darunavir Mylan), darunavir, Date of authorisation: 03/01/2017, Revision: 19, Status: Authorised
Evidence Dossier on Darunavir Viatris for HIV Treatment What is Established Darunavir Viatris is a generic antiviral medication authorized in the European Union for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. It contains the active…
Read →